Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK5 | Q00535 | 8/20 | 0.74 |
| ▸ | CDK5R1 | Q15078 | 8/20 | 0.74 |
| ▸ | CCNA2 | P20248 | 10/20 | 0.66 |
| ▸ | CDK2 | P24941 | 10/20 | 0.66 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 3/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | GSK3A | P49840 | 1/20 | 0.57 |
| ▸ | GSK3B | P49841 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7758141 | 0.93 | CCNA2 (0.76) | CDK5CDK5R1CCNA2CDK2ZAP70 | |
| SCHEMBL1251123 | 0.91 | MAPT (0.64) | CDK5CDK5R1CCNA2CDK2ZAP70 | |
| SCHEMBL20141868 | 0.90 | CDK5 (0.64) | CDK5CDK5R1CCNA2CDK2ZAP70 | |
| SCHEMBL25609823 | 0.86 | CCNA2 (0.70) | CDK5CDK5R1CCNA2CDK2ZAP70 | |
| SCHEMBL7757586 | 0.83 | CCNA2 (0.82) | CDK5CDK5R1CCNA2CDK2MAPT | |
| SCHEMBL4465180 | 0.82 | CCNA2 (0.82) | CDK5CDK5R1CCNA2CDK2ZAP70 | |
| SCHEMBL6605794 | 0.80 | CDK5 (0.58) | CDK5CDK5R1CCNA2CDK2ZAP70 | |
| SCHEMBL20142857 | 0.80 | GSK3A (0.67) | CDK5CDK5R1CCNA2CDK2ZAP70 | |
| SCHEMBL25609676 | 0.80 | CCNA2 (0.73) | CDK5CDK5R1CCNA2CDK2ZAP70 | |
| SCHEMBL1250778 | 0.80 | CCNA2 (1.00) | CDK5CDK5R1CCNA2CDK2ZAP70 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090312390-A1 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3 (GSK-3) FOR TREATING GLAUCOMA | ALCON, INC. (CH) | 2009-12-17 | — | — | US | claimed |
| EP-1430120-A4 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3 (GSK-3) FOR TREATING GLAUCOMA | ALCON INC (CH) | 2007-06-20 | — | — | EP | claimed |
| CN-1561393-A | Inhibitors of glycogen synthase kinase-3 (GSK-3) for the treatment of glaucoma | ALCON INC (CH) | 2005-01-05 | — | — | CN | claimed |
| US-20040186159-A1 | Inhibitors of glycogen synthase kinase-3 (gsk-3) for treating glaucoma | NOVARTIS AG (CH) | 2004-09-23 | — | — | US | claimed |
| EP-1430120-A1 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3 (GSK-3) FOR TREATING GLAUCOMA | Alcon, Inc. (CH) | 2004-06-23 | — | — | EP | claimed |
| WO-2003027275-A1 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3 (GSK-3) FOR TREATING GLAUCOMA | ALCON, INC. (CH) | 2003-04-03 | — | — | WO | claimed |
| EP-2281560-A1 | Inhibitors of glycogen synthase kinase-3 (GSK-3) for treating glaucomatous optic neuropathy | Alcon, Inc. (CH) | 2011-02-09 | — | — | EP | disclosed |
| US-20090312390-A1 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3 (GSK-3) FOR TREATING GLAUCOMA | ALCON, INC. (CH) | 2009-12-17 | — | — | US | disclosed |
| US-7598288-B2 | Inhibitors of glycogen synthase kinase-3 (GSK-3) for treating glaucoma | ALCON, INC. (CH) | 2009-10-06 | — | — | US | disclosed |
| EP-1430120-A4 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3 (GSK-3) FOR TREATING GLAUCOMA | ALCON INC (CH) | 2007-06-20 | — | — | EP | disclosed |
| CN-1561393-A | Inhibitors of glycogen synthase kinase-3 (GSK-3) for the treatment of glaucoma | ALCON INC (CH) | 2005-01-05 | — | — | CN | disclosed |
| US-20040186159-A1 | Inhibitors of glycogen synthase kinase-3 (gsk-3) for treating glaucoma | NOVARTIS AG (CH) | 2004-09-23 | — | — | US | disclosed |
| EP-1430120-A1 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3 (GSK-3) FOR TREATING GLAUCOMA | Alcon, Inc. (CH) | 2004-06-23 | — | — | EP | disclosed |
| WO-2003027275-A1 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3 (GSK-3) FOR TREATING GLAUCOMA | ALCON, INC. (CH) | 2003-04-03 | — | — | WO | disclosed |
| US-20010039275-A1 | Use of 2,4-diaminothiazole derivatives | NOVO NORDISK A/S (DK) | 2001-11-08 | — | — | US | disclosed |
| WO-2001056567-A1 | 2,4-DIAMINOTHIAZOLE DERIVATIVES AND THEIR USE AS GLYCOGEN SYNTHASE KINASE-3 (GSK-3) INHIBITORS | NOVO NORDISK A/S (DK) | 2001-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186159-A1 | Inhibitors of glycogen synthase kinase-3 (gsk-3) for treating glaucoma | GSK3B, GSK3A, GSKIP | CDK5 367/4885CDK5R1 778/4885CCNA2 4260/4885 |
| US-20090312390-A1 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3 (GSK-3) FOR TREATING GLAUCOMA | GSK3B, GSK3A, GSKIP | CDK5 367/4885CDK5R1 778/4885CCNA2 4260/4885 |
| US-20010039275-A1 | Use of 2,4-diaminothiazole derivatives | GSK3A, GSK3B, GSKIP | CDK5 923/4885CDK5R1 1286/4885CCNA2 3738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.